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ABSTRACT
Proﬂavine is an acridine dye used with high-resolution
microendoscopy for in vivo diagnostic evaluation of cervical
epithelial cells. However, there are concerns that even short-
term exposure of cervical tissue to dilute proﬂavine may
increase cervical cancer risk. We performed a retrospective
analysis of women referred for colposcopy to Barretos Can-
cer Hospital comparing the risk of cervical disease progres-
sion in those whose cervical tissue was (n = 232) or was not
exposed (n = 160) to proﬂavine. Patients in both groups
underwent treatment and follow-up based on histopathologic
results and per the local standards of care. Progression of
disease was evaluated by comparing histopathology from the
initial visit to the worst subsequent histopathology result
from all follow-up visits. Mean duration of follow-up was
18.7 and 20.1 months for the proﬂavine-exposed and controls
groups, respectively. There were no signiﬁcant differences in
disease progression from normal/CIN1 to CIN2/3 or from
any initial diagnosis to invasive cancer between the proﬂavine
exposed and control groups overall. Risks of cervical dys-
plasia progression observed in this study are in agreement
with those of the natural history of cervical cancer. Our
results suggest that cervical exposure to dilute proﬂavine
does not increase the risk of cervical precancer and cancer.
INTRODUCTION
Proﬂavine is a ﬂuorescent dye that has long been recognized and
used as a topical antibacterial agent. Its history of use as an
antiseptic in wound care dates back to the early 1900s, and its
action as a nucleic acid intercalator has been established as the
basis of its antibacterial properties (1,2). Today proﬂavine contin-
ues to be used as a commercially available antiseptic in many
parts of the world (3,4). Proﬂavine is one of the components of
triple dye, which is routinely used for umbilical cord care in
newborn infants in the United States (5,6). Toxicity of triple dye
is rare (6).
With the development of in vivo ﬁber-optic microscopy tech-
niques over the past two decades, proﬂavine and acriﬂavine (an-
other closely related acridine compound) have been frequently
used as topical contrast agents for optical imaging due to their
ability to ﬂuorescently label cell nuclei with high contrast. Acri-
ﬂavine has been reported as a contrast agent for in vivo confocal
laser endomicroscopy in the colon (7,8), stomach (9), duodenum
(10), upper gastrointestinal tract (11) and central airway (12). In
these studies, acriﬂavine was applied topically to the tissue prior
to imaging, usually in combination with intravenous ﬂuorescein.
Our group has reported the use of topically applied proﬂavine as
a contrast agent for in vivo microscopy in the oral cavity (13),
esophagus (14) and cervix (15). The use of proﬂavine or acri-
ﬂavine in combination with in vivo microscopy enables real-time
assessment of the morphology and distribution of cell nuclei, aid-
ing in the accurate identiﬁcation of precancerous lesions (16).
Despite their long history of safe clinical use, there remains
disagreement on the cancer risk of using proﬂavine and acri-
ﬂavine as contrast agents for in vivo imaging. In 1977, the
National Cancer Institute published a bioassay of proﬂavine for
possible carcinogenicity, based on administration of proﬂavine in
the diet to groups of rats and mice over a 2-year period (17).
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The bioassay was inconclusive due to an unusually high inci-
dence of carcinomas in control animals. The International
Agency for Research on Cancer (IARC) published evaluations of
the carcinogenic risk of acriﬂavine in 1977 (18) and of proﬂa-
vine in 1980 (19). These evaluations concluded that while acri-
ﬂavine and proﬂavine display mutagenicity in vitro, their
carcinogenic risk to humans could not be classiﬁed due to inade-
quate data in experimental animals and a lack of data in humans.
Some view the mutagenicity of these compounds in vitro as suf-
ﬁcient reason for concern. For example, a recent publication rec-
ommends the use of methylene blue over acriﬂavine as an
imaging contrast agent, due to concerns about the in vitro muta-
genicity of acriﬂavine (20). However, other recent publications
suggest that acriﬂavine and proﬂavine exhibit beneﬁcial anti-
cancer and antiviral effects. Acriﬂavine has been shown to
reduce tumor growth in mice by inhibiting HIF-1 dimerization
(21). An acriﬂavine and proﬂavine mixture has been shown to
elicit an antiviral immune response that signiﬁcantly reduced rhi-
novirus infection in mammalian cells (22). At this time, there is
no evidence demonstrating the carcinogenicity of proﬂavine or
acriﬂavine in human subjects, and as such, both compounds
remain categorized by the IARC as “not classiﬁable as to its car-
cinogenicity to humans” (23,24).
Yet concerns remain. Therefore, we conducted a retrospective
study to evaluate whether proﬂavine exposure is associated with
progression of cervical neoplasia in women with abnormal cervi-
cal cytology by comparing the rate of cervical intraepithelial neo-
plasia progression between two groups, one exposed to
proﬂavine and the other not exposed.
MATERIALS AND METHODS
Study participants. This is a historical cohort study. The proﬂavine group
was composed of women who had previously participated in a clinical trial
(ID# NCT02335372) at Barretos Cancer Hospital (Brazil) between June
2013 and January 2015. Participants in the trial were recruited from women
presenting for colposcopy due to abnormal cytology or previous history of
cervical dysplasia at the Prevention Department of Barretos Cancer
Hospital. This trial evaluated a new optical imaging device, the high-
resolution microendoscope (HRME), a portable, battery-powered
ﬂuorescence microscope with a ﬂexible ﬁber-optic probe (25–27). The
details of this experimental device have previously been described (15). As
part of the study protocol, 5% acetic acid was applied to the surface of the
uterine cervix and standard of care colposcopy was performed. This was
followed by application of 5% Lugol’s iodine solution. Proﬂavine solution
at a concentration of 0.01% was then applied to the cervix followed by
evaluation with the HRME probe. The typical volume dispensed by the
spray bottle was measured to be 3 mL with a range of 1–7 mL. The control
group was identiﬁed retrospectively and was balanced for severity of
baseline cytology diagnosis prior to colposcopy. The control group
comprised of women who underwent colposcopy and cervical biopsies in
the Prevention Department of Barretos Cancer hospital between May 2013
and May 2016. Patients in the control group did not undergo evaluation
with HRME and thus were not exposed to proﬂavine; however, they were
subjected to equivalent diagnostic, treatment and follow-up procedures.
This retrospective study was approved by the Barretos Cancer Hospital
Ethics Research Committee, the Brazilian National Ethics Research
Commission (CAAE: 83227718.8.0000.5437).
Follow-up and treatment. Follow-up data including all histopathology
results were collected for patients in both groups from the time of the
initial colposcopy until the last appointment available from the medical
record. In both groups, the treatment and follow-up were performed
according to the local standard of care based on histopathology results.
Those women diagnosed with cervical intraepithelial neoplasia grades 2
(CIN 2) or 3 (CIN 3) underwent treatment with loop electrosurgical
excision procedure (LEEP). Those diagnosed with invasive cancer were
referred to the Gynecologic Oncology department for care.
Statistical analysis. Data for all patients in the proﬂavine and control
groups were collected from electronic medical records at Barretos Cancer
Hospital and compiled into an SPSS database ﬁle. The database consisted
of a total 499 patient records with 299 records in the proﬂavine group
and 200 in the control group. The following data ﬁelds were aggregated
for each participant: age, study group, initial cytology result, date of
initial colposcopy, initial histopathology result, date of last clinical visit
and up to six subsequent histopathology results. For all histopathology
results, the date of diagnosis and tissue specimen type (cervical biopsy,
endocervical curettage (ECC), LEEP, or hysterectomy) were documented.
The total follow-up time period was calculated as the time between the
ﬁrst and last colposcopy evaluations on record.
Cervical cytology results were grouped into two categories: normal/low
grade and high grade. Normal/low grade included the following: negative for
intraepithelial lesions or malignancy (NILM), atypical squamous cells of
undetermined signiﬁcance (ASC-US) and low-grade squamous intraepithe-
lial lesion (LSIL). High-grade cytology results included: high-grade squa-
mous intraepithelial lesion (HSIL), atypical squamous cells cannot exclude
high-grade squamous intraepithelial lesion (ASC-H), atypical glandular cells
(AGC), squamous cell carcinoma and adenocarcinoma. In order to assess
cervical dysplasia progression, histopathology results were grouped into ﬁve
clinically relevant categories by increasing severity of diagnosis: negative for
intraepithelial lesion (NIL), cervical intraepithelial neoplasia grade 1 (CIN
1), CIN 2 or CIN 3 (CIN 2/3), adenocarcinoma in-situ (AIS) and invasive
cancer. NIL category included diagnoses of normal, inﬂammation, hyper-
plasia and metaplasia. CIN 2/3 category included diagnoses of CIN 2, CIN
3 and CIN 2/3. Invasive cancer category included diagnoses of invasive
squamous cell carcinoma and adenocarcinoma. In cases where follow-up
colposcopy was negative and no biopsies were obtained, the visit was cate-
gorized as normal colposcopy/no biopsy performed.
A total of 107 patients were excluded from the analysis for the follow-
ing reasons: (1) total follow-up duration was less than 6 months (proﬂavine
group, n = 49; control group, n = 29), and (2) patient had an initial histo-
logical diagnosis of invasive carcinoma (proﬂavine group, n = 18; control
group, n = 11). After applying these exclusion criteria, 392 patients were
included in the retrospective analysis (proﬂavine group, n = 232; control
group, n = 160). Using these data, the study population was characterized
using descriptive statistics. Categorical variables were compared using
Fisher’s exact test, and continuous numerical variables were compared
using Student’s t test. Survival analysis was performed on two clinical end-
points: (1) progression from a baseline histopathologic diagnosis of <CIN2
to a subsequent histopathologic diagnosis of CIN2+, (2) treatment via
LEEP. A spreadsheet containing all patients was compiled with the follow-
ing information: cohort (proﬂavine or control), time from baseline diagno-
sis to the event of interest (days), and the status (1 = event occurred,
0 = event not occurred) at the indicated time interval. A survival function
was ﬁt using the “survival” package of the R programming language (28).
The functions for both proﬂavine and control cohorts were plotted over
time and the resulting ﬁts compared using the G-rho family of tests (29).
Statistical signiﬁcance level was set at 5%. Post hoc statistical power was
calculated using PASS (NCSS LLC, Kaysville, UT, USA).
RESULTS
Baseline patient characteristics
There were no statistically signiﬁcant differences between groups
according to their initial diagnosis by cytology and/or histopathol-
ogy from cervical biopsies (Table 1). The mean age at diagnosis
was slightly higher in the control arm (mean = 37.8 years;
SD = 13.0 years) in comparison with the proﬂavine arm
(mean = 35.8 years; SD = 11.7 years) but not statistically signiﬁ-
cant (P = 0.10). The mean time of follow-up was 18.7 months
(SD = 6.0 months) and 20.1 months (SD = 5.6 months) for the
proﬂavine and control groups, respectively.
Cervical dysplasia progression
In order to evaluate cervical dysplasia progression, we compared
initial and subsequent worst histopathologic diagnoses for the
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patients exposed to proﬂavine (n = 232) and those not exposed
(n = 160). Because removal of proﬂavine-exposed tissue via
LEEP may mitigate the effect of proﬂavine exposure, we
stratiﬁed our analysis within each cohort by those who under-
went LEEP and those who did not. A LEEP was performed in
124 of the 232 (53%) patients exposed to proﬂavine and in 96
of the 160 (60%) control patients (P = 0.21).
Table 2 shows the initial and subsequent worst diagnoses for
patients who did not undergo LEEP in the proﬂavine and control
groups, respectively. There were a total of nine patients that had
benign histopathology who had a subsequent diagnosis of CIN 1
(proﬂavine 5%; control 6%; P = 0.73). Additionally, there was
one patient in the control group that progressed from an initial
diagnosis of CIN 1 to CIN 2/3 (proﬂavine 0%; control 2%). The
majority of non-LEEP patients had no abnormal cervical lesions
observed during follow-up colposcopy, and thus, no additional
cervical biopsies were required (proﬂavine 52%; control 58%;
P = 0.53).
Table 3 provides a similar summary of initial and ﬁnal
histopathology for patients in both study groups that did undergo
LEEP during the follow-up period. The most common initial
biopsy diagnosis in both patient populations was CIN 2/3, which
was subsequently equally conﬁrmed by the diagnosis on the
Table 1. Baseline diagnosis according to the study group.
Study Group
P-value*
Proﬂavine Exposed
(n = 232, %)
Control
(n = 160, %)
Cytology
Normal/low-grade 54 (23.3) 36 (22.5) 0.90
High-grade 178 (76.7) 124 (77.5)
Histopathology
<CIN2 125 (53.9) 77 (48.1) 0.30
CIN2+ 107 (46.1) 83 (51.9)
Normal/low grade = NILM, ASC-US, LSIL; High grade = ASC-H,
AGC, HSIL, Carcinoma, Adenocarcinoma; < CIN2 = Cervicitis, Hyper-
plasia, Metaplasia, CIN1, CIN2+ = CIN 2, CIN 3, Adenocarcinoma
In-situ, Carcinoma, Adenocarcinoma. *P-values calculated using Fisher’s
exact test.
Table 2. Initial and worst subsequent pathologic diagnoses for patients who did not undergo LEEP.
Exposed to Proﬂavine and did not Undergo LEEP
(n = 108/232, 47%)
Not Exposed to Proﬂavine and did not Undergo LEEP
(n = 64/160, 40%)
Worst Subsequent Pathologic Diagnosis Worst Subsequent Pathologic Diagnosis
Normal
Colposcopy/
No Biopsy
(%)
NIL
(%)
CIN 1
(%)
CIN 2/3
(%)
AIS
(%)
Invasive
Cancer
(%)
Total
(%)
Normal
Colposcopy/
No Biopsy
(%)
NIL
(%)
CIN 1
(%)
CIN 2/3
(%)
AIS
(%)
Invasive
Cancer
(%)
Total
(%)
Initial Pathologic Diagnosis
NIL 10 (9) 2 (2) 5 (5) 0 (0) 0 (0) 0 (0) 17 (16) 17 (27) 7 (11) 4 (6) 0 (0) 0 (0) 0 (0) 28 (44)
CIN 1 45 (42) 12 (11) 28 (26) 0 (0) 0 (0) 0 (0) 85 (79) 19 (30) 2 (3) 7 (11) 1 (2) 0 (0) 0 (0) 29 (45)
CIN 2/3 1 (1) 0 (0) 2 (2) 3 (3) 0 (0) 0 (0) 6 (6) 1 (2) 1 (2) 1 (2) 4 (6) 0 (0) 0 (0) 7 (11)
AIS 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 56 (52) 14 (13) 35 (32) 3 (3) 0 (0) 0 (0) 108 (100) 37 (58) 10 (16) 12 (19) 5 (8) 0 (0) 0 (0) 64 (100)
, Cases where subsequent pathology was equal to initial; , Cases where subsequent pathology was worse than initial. Normal Colposcopy/No
Biopsy = Follow-up colposcopy examinations were normal and did not require additional biopsies; NIL = Negative for Intraepithelial Lesion (normal,
inﬂammation, hyperplasia and metaplasia); CIN 1 = Cervical Intraepithelial Neoplasia Grade 1; CIN 2/3 = Cervical Intraepithelial Neoplasia Grades 2, 3
and 2/3; AIS = Adenocarcinoma In-situ; Invasive Cancer = Invasive adenocarcinoma.
Table 3. Initial and worst subsequent pathologic diagnoses for patients who underwent LEEP.
Exposed to Proﬂavine and Underwent LEEP
(%)(n = 124/232, 53%)
Not Exposed to Proﬂavine and Underwent LEEP
(%)(n = 96/160, 60%)
Worst Subsequent Pathologic Diagnosis Worst Subsequent Pathologic Diagnosis
Normal
Colposcopy/
No Biopsy
(%)
NIL
(%)
CIN 1
(%)
CIN 2/3
(%)
AIS
(%)
Invasive
Cancer
(%)
Total
(%)
Normal
Colposcopy/
No Biopsy
(%)
NIL
(%)
CIN 1
(%)
CIN 2/3
(%)
AIS
(%)
Invasive
Cancer
(%)
Total
(%)
Initial Pathologic Diagnosis
NIL 0 (0) 1 (1) 0 (0) 6 (5) 0 (0) 0 (0) 7 (6) 0 (0) 0 (0) 3 (3) 4 (4) 0 (0) 1 (1) 8 (8)
CIN 1 0 (0) 0 (0) 7 (6) 9 (7) 0 (0) 0 (0) 16 (13) 0 (0) 0 (0) 3 (3) 9 (9) 0 (0) 0 (0) 12 (13)
CIN 2/3 0 (0) 8 (6) 11 (9) 81 (65) 0 (0) 0 (0) 100 (81) 0 (0) 5 (5) 8 (8) 63 (66) 0 (0) 0 (0) 76 (79)
AIS 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 0 (0) 9 (7) 18 (15) 96 (77) 0 (0) 1 (1) 124 (100) 0 (0) 5 (5) 14 (15) 76 (79) 0 (0) 1 (1) 96 (100)
, Cases where subsequent pathology was equal to initial; , Cases where subsequent pathology was worse than initial; Normal Colposcopy/No
Biopsy = Follow-up colposcopy examinations were normal and did not require additional biopsies; NIL = Negative for Intraepithelial Lesion (normal,
inﬂammation, hyperplasia and metaplasia); CIN 1 = Cervical Intraepithelial Neoplasia Grade 1; CIN 2/3 = Cervical Intraepithelial Neoplasia Grades 2, 3
and 2/3; AIS = Adenocarcinoma In-situ; Invasive Cancer = Invasive adenocarincoma.
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Table 4. Summary of cases where subsequent pathologic diagnosis was worse than baseline diagnosis.
All Patients Did Not Undergo LEEP Underwent LEEP
Initial
Diagnosis
Worst
Subsequent
Diagnosis
Proﬂavine
Exposure
(n = 232)
(%)
No Exposure
(n = 160)
(%) P-value*
Proﬂavine
Exposure
(n = 108)
(%)
No Exposure
(n = 64)
(%) P-value
Proﬂavine
Exposure
(n = 124)
(%)
No Exposure
(n = 96)
(%) P-value
NIL CIN 1 5 (2.2) 7 (4.4) 0.19 5 (4.6) 4 (6.3) 0.50 0 (0) 3 (3.1) 0.35
NIL CIN 2/3 6 (2.6) 4 (2.5) 0 (0) 0 (0) 6 (4.8) 4 (4.2)
CIN 1 CIN 2/3 9 (3.9) 10 (6.3) 0 (0) 1 (1.6) 9 (7.3) 9 (9.4)
NIL Invasive Cancer 0 (0) 1 (0.6) 0 (0) 0 (0) 0 (0) 1 (1.0)
AIS Invasive Cancer 1 (0.4) 0 (0) 0 (0) 0 (0) 1 (0.8) 0 (0)
Total 21 (9.1) 22 (13.8) 5 (4.6) 5 (7.8) 16 (12.9) 17 (17.7)
*P-values calculated using Fisher’s exact test based on total cases where subsequent diagnosis was worse than initial.
Figure 1. Kaplan–Meier estimate of (a) progression from <CIN2 to CIN2 + and (b) surgical treatment (LEEP). Vertical tick marks represent censoring
at the indicated time point. Statistical comparisons were performed using a log-rank test.
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LEEP tissue (proﬂavine 65%; control 66%; P = 1.0). There were
28 patients with benign initial histopathology on biopsy who had
a worst subsequent diagnosis of CIN 2/3 on the LEEP tissue
(proﬂavine 12%; control 13%). In addition, three patients in the
control group had benign initial histopathology with a worst sub-
sequent diagnosis of CIN 1 (proﬂavine 0%; control 3%). One
invasive cervical cancer was diagnosed both in the proﬂavine
exposed and control groups.
The risks of cervical dysplasia progression for all groups are
summarized in Table 4. Progression from normal/CIN1 to CIN 2/3
was noted in 15/232 (6.5%) proﬂavine-exposed patients and 14/160
(8.8%) of controls (P = 0.44). Progression from any initial diagno-
sis to invasive cancer was noted in one of 232 patients exposed to
proﬂavine (0.4%) and one of 160 controls (0.6%) (P = 1.0). Based
on the total number of cases where subsequent pathology was
worse than initial, there were no statistically signiﬁcant differences
in progression of cervical dysplasia between proﬂavine-exposed
and nonexposed patients (Table 4) (all patients: P = 0.19; non-
LEEP patients: P = 0.50; LEEP patients: P = 0.35).
Figure 1 shows a Kaplan–Meier estimate of two clinical end-
points: progression from a baseline histopathologic diagnosis of
<CIN2 to a subsequent histopathologic diagnosis of CIN2+ (pro-
ﬂavine group, n = 125; control group, n = 77) and treatment via
LEEP (proﬂavine group, n = 232; control group, n = 160). No
statistically signiﬁcant difference was found for progression of
histological diagnosis from <CIN2 to CIN2+ between proﬂavine-
exposed and control groups (log-rank test, p = 0.21). Addition-
ally, no statistically signiﬁcant difference was found for treatment
by LEEP between proﬂavine-exposed and control groups (log-
rank test, P = 0.32).
DISCUSSION
In this study, we assessed whether proﬂavine might increase the
risk of cervical neoplasia progression when used as a ﬂuorescent
contrast agent for in vivo microscopy during colposcopic exami-
nation. Our results showed no signiﬁcant increases in cervical
dysplasia progression in women exposed to proﬂavine when
compared to a control group of nonexposed women. This is
important for routine gynecological examinations because proﬂa-
vine can be used as a diagnostic tool in conjunction with col-
poscopy, facilitating the recognition of cervical lesions through
in vivo microscopy as previously reported by Grant et al. (15).
The primary contribution of this study is to provide initial data
regarding the use of proﬂavine in human subjects with cervical
dysplasia. We are not aware of any prior studies assessing proﬂa-
vine and cervical dysplasia progression; however, these results
may also be put into context of other studies investigating the
natural history of cervical dysplasia.
In a meta-analysis of 17 studies involving 4504 participants,
€Ostӧr (30) found that 10% of women with CIN 1 will progress
to CIN 3 and only 1% will progress to invasive cancer. Follow-
up durations in this meta-analysis varied widely from as little as
3 weeks up to 25 years (30). A more recent analysis of 524
patients from the placebo arm of the quadrivalent HPV vaccine
trials found that 12% of patients with initial diagnosis of CIN 1
developed CIN 2/3 during follow-up (31). The ﬁndings in this
study are in agreement with previously established risks.
The total follow-up duration achieved by this analysis is one
limitation of the study. Even with this limitation, the structure of
this study provides a meaningful comparison for cervical dys-
plasia progression in proﬂavine-exposed and nonexposed sub-
jects. The post hoc statistical power was ≥80% (a = 0.05) to
detect an absolute increase in risk of upstaging from <CIN2 to
CIN2+ of 18% (or more). However, longer-term follow-up stud-
ies with larger sample sizes will be necessary to provide reassur-
ance for the topical use of proﬂavine on the cervical epithelium.
In conclusion, the risks of cervical dysplasia progression
observed in this study are in agreement with those of the natural
history of cervical cancer. Our ﬁndings suggest that cervical pro-
ﬂavine exposure is not associated with acute disease progression
in women with cervical dysplasia.
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